Verve Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Verve Therapeutics's earnings have been declining at an average annual rate of -32.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 121.2% per year.
Anahtar bilgiler
-32.4%
Kazanç büyüme oranı
59.1%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 121.2% |
Özkaynak getirisi | -35.3% |
Net Marj | -933.0% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Gelir ve Gider Dağılımı
Verve Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 21 | -193 | 53 | 0 |
31 Mar 24 | 16 | -197 | 52 | 0 |
31 Dec 23 | 12 | -200 | 50 | 0 |
30 Sep 23 | 8 | -193 | 49 | 0 |
30 Jun 23 | 5 | -192 | 47 | 0 |
31 Mar 23 | 3 | -179 | 43 | 0 |
31 Dec 22 | 2 | -157 | 38 | 0 |
30 Sep 22 | 1 | -148 | 33 | 0 |
30 Jun 22 | 0 | -125 | 29 | -25 |
31 Mar 22 | 0 | -137 | 24 | -11 |
31 Dec 21 | 0 | -120 | 19 | 0 |
30 Sep 21 | 0 | -113 | 14 | 16 |
30 Jun 21 | 0 | -99 | 10 | 48 |
31 Mar 21 | 0 | -53 | 7 | 40 |
31 Dec 20 | 0 | -46 | 5 | 0 |
Kaliteli Kazançlar: VERV is currently unprofitable.
Büyüyen Kar Marjı: VERV is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: VERV is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Büyüme Hızlandırma: Unable to compare VERV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: VERV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: VERV has a negative Return on Equity (-35.28%), as it is currently unprofitable.